Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.

MLA

Gong, Xiaohua, et al. “Evaluation of the Clinical Cardiac Safety of Pemigatinib, a Fibroblast Growth Factor Receptor Inhibitor, in Participants with Advanced Malignancies.” Pharmacology Research & Perspectives, vol. 10, no. 1, Feb. 2022, p. e00906. EBSCOhost, https://doi.org/10.1002/prp2.906.

APA

Gong, X., Ji, T., Liu, X., Chen, X., & Yeleswaram, S. (2022). Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies. Pharmacology Research & Perspectives, 10(1), e00906. https://doi.org/10.1002/prp2.906

Chicago

Gong, Xiaohua, Tao Ji, Xiang Liu, Xuejun Chen, and Swamy Yeleswaram. 2022. “Evaluation of the Clinical Cardiac Safety of Pemigatinib, a Fibroblast Growth Factor Receptor Inhibitor, in Participants with Advanced Malignancies.” Pharmacology Research & Perspectives 10 (1): e00906. doi:10.1002/prp2.906.